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· · · · · · · · · Radi~t~~~ ·~~d~~~d. ~~~~s;~~ ;~ ~. ~~~· ~~~~~~-·~~;~~~;~. ~~~~g 
• · · · tre·acr ana ·neO< . ca"ricer· pai:i"e"nts. during . radiothe~apy ~ Th~· i~t~~~~. of 
.... mucositis .\taries a~core~g to ·differen.t t~atmerft" p~ra"mefers. arid can 
be reduced by physical and P.tJC!r.OJ~CQiogicaJ .lnter..v.ention. · T~ls· Js. a 
......................... • . . . . . . . 
randomlsed trial to evaluate the efficacy of topical natural honey to 
. . . . . . . . . . . . . . . . . . . . . . . . .. 
· · · · ·p·revenf radiation· mucositi_s: i=oriY diagnosed cancer patients requiring 
.... radiation. to. the . head· -anct ·neck ·area· we:re 4 ran~omlsed · t'o· "receive 
. " . " 
·radiation atone_ or 'ta.d,i~i9tl. PillS J:opical .applicatioo of -13~re ·natural 
••.••••••..••••• ·.p • • • • . . . . . 
honey. Pattents were treate~ using a 6-MY.'!~~~r. ~~~e.1~r:a~9r,. <4~ 9 .d.o:;e 
••• 
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·rafe of 2'Gy "pe"r'day ~reating·s-ti~e~ ~· ~eek up to a dose of 60-70 Gy. 
· · · · Ir:a·the· st-Udy arm,· patl_ents ·werE! atJvis"e"ci to take "i6 ·miililitres of .p.ure 
. . . . ·.h9!1~Y. ~~ .n:H.n.u.t~s. befare., . is _minute .after; ·and 6· hoars post radiation 
therapy. Patients were -evaluated ev~ry. ~~e.k. fQr. tile .de.v.eJ_opment .of 
· · · · i-acnatiori. ·n,uco~iti~ · ~~i·n·~ ·.Rl-oCi. ~rading system. The study was 
..... condtJcted "betweer1 "N6veilioer "2'r56cf "arid' Octobe~. iooi." ·,;,·~·r~. ~~s 
· .... ~!Q'1i~~~t. reductioo.ln the. symptemati(:4 grade•3/'4' mll~~~fis ·among ~ 
honey treated patients· -compared t~. C:(!f!trQI.Si J,~ .. 2Q 0/a VerSUS. 759/a {p 
~ ~ · · b~.666s8j. ~the ··ma~i~~·~ · i~t~·~~it; of mucositis was observed towards 
• • • • srcL w~· of ·rcl"cnottit~r~py ·on. ·ooth · ar~·s: . i"t1e . ~ompii~~~~. ~i i,~~~v 
..• - b:~a.ted ~gr.o.up. _of .p~tieRtS was better- than· t:ontrdiS." FiftY 'five~ perce"nt 
( 55°/o) of patients tr~a~e.q ."'!I~~ . t.OP.it;a.l. t)QOey .~hawed~ no -Gllange or 
.. . . . . . . . . . . . . . . . . . . . . . . . . . . 
positive gain of body weight compared to 25°/~ in the control arm (p 
· · · · ~:053)". ·rn· tOntru·sion; l:opica·l·application· of nat~;a·J ·h~~~~ ~~ ~. ~i~~le 
_ .... p{l(J.~o.st-:effe~tve treatment ~A f'St:!iattan mucasltlS,~which· rieed ·rurt:h"er 
multi centre randomlsed trials to valid.a~~ .o.ttr)lnding .. · ............ · 
· · · · ii.fii ·WOrd~:·. ;.;di~t~~·~. ~~~~~~~~~; acute morbidity, honey, and· 
treatment 
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Abstract 
Radiation induced mucositis is. a very common morbidity among head 
and neck cancer patients during radiotherapy. The intensity of 
mucositis varies according to different treatment parameters and can 
be reduced by physical and pharmacological intervention. This Is a 
randomised trial to evaluate the efficacy of topical natural honey to 
prevent radiation mucositis. Forty diagnosed cancer patients requiring 
radiation to the head and neck area were randomlsed to receive 
radiation alone or radiation plus topical application of pure natural 
honey. Patients were treated using a 6-MV linear accelerator, at a dose 
rate of 2 Gy per day treating 5-tlmes a week up to a dose of 60-70 Gy. 
In the study arm, patients were advised to take 20 millilitres of pure 
honey 15 minutes before, 15 minute after, and 6 hours post radiation 
therapy. Patients were evaluated every week for the development of 
radiation mucositis using RTOG grading system. The study was 
conducted between November 2000 and October 2001. There was 
significant reduction in the symptomatic grade-3/4 mucositis among 
honey treated patients compared to controls; I.e. 20°/o versus 75°/o (p 
0.00058). The maximum Intensity of mucositis was observed towards 
3rd weeks of radiotherapy on both arms. The compliance of honey 
treated group of patients was better than controls. Fifty five percent 
( 55°/o) of patients treated with topical honey showed no change or 
positive gain of body weight compared to 25°/o in the control arm (p 
0.053). In conclusion, topical application of natural honey Is a simple 
and cost-effective treatment In radiation mucositis, which need further 
multi centre randomised trials to validate our finding. 
Key words: radiation mucositis, acute morbidity, honey, and 
treatment 
3 
Introduction 
Management of head and neck cancer has undergone tremendous 
changes over the past 3-decades, with emphasis on organ 
preservation and multimodality management, Including use of 
chemoirradiation. The latter approach Is always associated with 
increased toxicity due to mucositis resulting in non-compliance to 
radiotherapy. About 500,000 newly diagnosed head and neck cancer 
cases are discovered worldwide1• Majority of these patients received 
chemotherapy, radiotherapy alone or In combination. However tile 
degree of acute radiation morbidities depends upon the type and 
technique of chemotherapy and radiotherapy. 
Radiation induced mucositis is an Important complication of head and 
neck radiotherapy. Exposure of ionizing radiation to oral, pharyngeal 
and laryngeal n1ucosa gives rise to radiation epithelitls towards the 3rd 
week of conventional fractionated radiotherapy2 • Severe radiation 
mucositis lead to ulceration and painful dysphagia that leads to poor 
quality of life and treatment discontinuation. The intensity of mucositis 
depends on the field size, Interval between fractions, dose-per-fraction, 
previous exposure to chemotherapy, concurrent chen1otherapy or co-
morbid medical conditions lil<e diabetes mellitu5 or connecuve vascular 
disorders. The development of the oral mucositis is an Inevitable 
accompaniment of radiation therapy to the head and neck region . The 
incidence of significant (grade 3 & 4) mucositis varies from 25 °/o to 50 
0/o in various reported series 3 -6 • There are various means to reduce 
incidence of radiation mucositis. The most common technique is to 
shield the unaffected mucosa by lead shields, use of conformation 
therapy, use of mouth bites, decreasing dose-per-fraction, and 
deliberate use of treatment breaks7 • The above principles do not suit in 
certain circumstances like large tumour volume, and possibility of 
tumour resistance due to treatment gap. 
The treatment of radiation- induced mucositis is not well established. 
However, many agents like topical sucralfate8 , subcutaneous or topical 
granulocyte macrophage colony stimulating factors (GM-CSF)9-10, 
prostaglandin-E analogue misoprostol11 , topical corticosteroids12 , and 
parenteral radio-protector arnifostlne13 have been tried with various 
response rates. Currently studies are on to find out newer agents, 
which are effect ive, safe and easy to use. 
Honey is the concentrates of pollens f rom flowers collected by honey-
bee. Though honey is an age-old remedy from the t ime of Egyptian 
civilisation, very recently it has found place in the modern medical 
5 
literature14•15• Honey has been found to be effective In burn wound, oral 
infections and healing of surgical wounds16-18 • Honey has antibacterial 
properties and enhances epithelization thereby Improve wound 
healing19• Researchers found a natural. resin from honey, which are 
potent inhibitor of human colon adenocarcinoma cell growth, 
carcinogenic Induction, biochemical changes and paraneoplastic lesion 
changes of rat colon20 • Here we have used natural honey for the 
treatment of radiation mucositis to enhance epithelization of the 
mucosa, thereby reduce morbidity. 
Materials and methods 
Between November 2000 to October 2001, 40-patients undergoing 
radiotherapy to the head and neck region were randomised to receive 
either topical application of natural honey along with radiotherapy ·..:r 
radiotherapy alone. All the patient's treatment p.arameters were 
recorded In a special entry form. The quality-of-life (QoL) was 
measured before and after completion of radiotherapy using EORTC-
QLQ-C30 (version 2.0) questionnaire. Patient's informed consent was 
obtained before starting radiotherapy. 
Radiotherapy 
Radiotherapy was administered using a 6-MV linear accelerator. The 
tumour volumes were assessed prior to simulation and adequate 
margins were taken depending upon the type of malignancy. Usually 
6 
parallel-opposed fields were used and tumour dose was calculated at 
-• 
the mid-plane. In multi-field ·technique, individual dose calculation 
technique was used. Conventional fractionated radiation was delivered 
to the tumour volume at a dose rate of 2-Gy per fraction, treating 5-
fractions per week to a total period of 6-7 weekso Individualised 
thermoplastic cast were made to treat tumours of the mobile parts of 
head and neck areas. External beam radiotherapy was delivered in 
three phases using shrinking field technlq~e. 
Assessment of the tumour response and development of complication 
was monitored every week on usual radiotherapy review clinic. Body 
weight recording and full blood count examination was performed on 
every assessment visit. Baseline liver function test, kidney function 
test, and blood sugar level were estimated before and after completion 
of radiotherapy. The development of mucositis was assessed using 
clinical and mirror examination of the mucosa. Radiotherapy and 
oncology Group (RTOG) grading was utilised to grade the mucosltls21 • 
The treatment delays or gap are recorded In case of Interval due to 
Intolerable mucositis 
Randomisation 
Patients were randomised using the randomisation service of web site 
tlt.t.P--~Lww.w~r~ndorutzg_t_LQJl!.~Q.n1. The patients were recruited as per the 
randomisation sequence for study and control arm patients. In the 
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treatment arm, pure natural honey was used. The patients were asked 
to take 20 ml of natural honey before radiotherapy, 20 ml after 
radiotherapy and 20 ml 6 hours there after. The patients were advised 
to rinse honey on the oral mucosa and then to swallow slowly to smear 
on the oral and pharyngeal mucosa. Both treatment and control arm 
patients were advised for adequate fluid Intake and supplement high-
protein diet. 
Quality control of Honey 
Honey used In this trial was obtained from the pure extracts of the 
beehives from the Malaysian rain forest. The above-obtained extract 
was filtered and supplied as raw or pur~ honey for the trial. The honey 
was subjected to chemical analysis and the pH was measured. A thin 
layer chromatography was used for the chemical analysis. The agent 
was extracted with potassium ether, chloroform, ethyl alcohol, methyl 
alcohol and developed to meet MeOH : H20 : CHCI3 proportion of 
so: 10:64. Vanllyn sulphuric acid test was done to find out glycoside 
compounds. Microbiological assay was done against pathogenic 
organisms at pure, 1:2, 1:4 and 1:8 dilutions respectively. Culture of 
Pseudomonas auroginosa. Streptococcus pyogenes. Staphylococcus 
aureus, and Escherichia coli were plated on agar plate. A filter disc was 
placed on the medium. About 30J.LI of the neat and 1':2, 1:4 and 1:8 
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diluted honey was placed on the disk. The medium was Incubated for 
18 hours and the Inhibition zone was measured. 
Response and toxicity criteria 
The tumour regression was observed every week . during radiation 
therapy and a-weeks after completion of radiotherapy. The response 
measurement was done purely on clinical examination. Patients with 
complete regression of tumour was defined as complete response (CR), 
regression from 50o/o to 99°/o as partial response (P~), and less than 
50°/o response as no response (NR). Development of oral and 
pharyngeal mucositis was grades as 0 for no change, 1 for mucosal 
erythema, 2 for studded mucositis, 3 for confluent mucositis not 
requiring intervention and 4 for ulceration, which necessitate treatment 
break as per the specifications of RTOG grading system21 0 
Qualit·y of life assessment 
All patients were subjected to quality of life questionnaire as 
recommended by EORTC22• This is a questionnaire containing 43-
questions related to the well being of the patients evaluated before and 
after completion of radiotherapy course. 
Analysis 
All the patients demographic and treatment related and morbidity 
scores were analysed using Microsoft-Excel software. The difference 
between the morbidities, nutritional parameters, treatment breaks and 
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total duration of mucositis etc was compared using Chi-square 
comparison from EPI Info 2000 software. 
Results 
The study was completed in October 2001 and all the cases received 
radiotherapy as planned. The primary tumours were distributed in 
nasopharynx (9), larynx (7), paranasal sinuses (7), Thyroid (5) and 
other miscellaneous sites (12) (Table-1) The honey was subjected to 
microbiological assay to evaluate Its antibacterial potency before 
administration to the patients, The honey showed good Inhibition of 
bacterial growth proportionate to its concentration (Figure-l.a, b, c, d). 
Organisms like Pseudomonas auroginosa, Escherichia coli, 
Streptococcus pyogenes and staphylococcus aurlous colonies showed 
good growth Inhibition in vitro. Chemical analysis of the honey sample 
showed a pH of 4.8 and contains 5 compounds of terplnoids, 
tetraphenolds, trace elements, nitrogenous compounds, glycosldes and 
sugars. 
In the treatment arm, 16 patients showed some form of radiation 
mucositis, where as 19 patients In the control arm exhibited radiation 

Table-l.Patieng ~tharacteristftcl 
Total number of patients 
Controls 
Study arm 
Male: Female Ratio 
Controls 
Study arm 
Age distribution (years) 
Controls 
Treatment arm 
Tumor location/ TNM classification 
T -category Control 
Tl 00 
T2 01 
T3 OS 
T4 12 
NO 04 
Nl 06 
N2 04 
N3 03 
M1 00 
Location 
Nasopharynx 06 
Larynx 01 
Paranasal sinus OS 
Thyroid 03 
Miscellanenous sites 05 
Mean radiation 132 cm2 
field size 
40 
20 
20 
8:12 
15:5 
14 (minimum) 
54 (median) 
78 (maximum) 
19 (minin1um) 
63 (median) 
89 (maximum) 
Study arm 
01 
01 
03 
12 
06 
03 
02 
04 
02 
03 
06 
01 
02 
06 
153.4cm2 
' I 
!- Table-2.0ral mucositis in honey-treated and control group of patients 
Number of patients 20 20 NS 
Patients with mucositis 16 19 NS 
Patients with grade-3/4 mucositis 04 15 0.0005838 
Mean grade of mucositis 3.05 3.3 NS 
II Mean onset of mucositis (week) 3 3 NS 
- -~------·-·----------·------
Mean total duration of mucositis 07 07 NS 
Negative body weight 09 1 l NS 
Static or positive body weight 11 05 0.0532299 
Mean treatment breaks (days) 19.5 18 NS 
Table-3.Distribution of mucositis during radiotherapy course 
Controls Week-I Week-2 Week-3 Week-4 Week-5 Week-6 Week-7 Total 
-----·-f-· 05 04 GO 16 07 09 11 16 68 
'--
G1 05 05 03 03 01 01 01 18 
- -
- --
G2 Ol 08 08 02 05 03 02 29 
G3 01 02 04 07 05 03 01 23 _ .. __ . 
G4 00 00 OJ 01 00 02 00 04 
--
.. 
Treatment 
------
GO 14 12 06 07 10 13 17 79 
-
06 05 07 05 07 G1 04 02 J6 
--- 03 1-· -
___ .., ____ 
G2 00 05 06 03 03 01 21 
--- 00 00 02 . 02 00 00 00 04 G3 
- ··----·------
r-- 00 00 00 00 00 00 00 00 G4 
E. coli 
I 
1:8 diluted hon 
I to 
1 
1:4 diluted honey 1 :2 diluted honey 
FIG - ln. 
Pseudo~nasaerugunosa 
1:8 diluted honey Undiluted honey 
• 0 
1:4 diluted 1 :2 diluted honey 
FIG - lb 
• 
r 
I 
r 
r 
1 1:8 diluted honey 
r 
r 1:4 diluted honey 
' 1 :8 diluted hon 
:4 diluted honey 
Staphylococcus aureus 
1 :2 diluted honey 
FIG - lc 
Streptococcus pyogenes 
:.....;..:.,._. Undiluted honey 
1 :2 diluted honey 
FIG - ld 
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mucositis. The difference in the grade-3/4 mucositis was 20°/o and 75°/o 
respectively in the treatment and control arm (Table-2). The above 
finding was statistically significant (p0.00058). The mean grade of 
mucositis was 3.05 and 3.3 respectively, but the mean onset of 
mucositis was on the 3rd week of radioth'erapy on both arms (Table-3). 
The treatment breaks in both arms were almost same. In the 
evaluation of weekly body weight, 9 patients from study arm and 11 
patients from control arm showed some extent of loss of body weight. 
But interestingly 55°/o of the honey treated patients showed either 
static or positive gain in body weight during radiotherapy in comparison 
to 25°/o in the control arm. The difference in the patterns of mucositis 
in both arms is illustrated in figute-2a & 2b, which showed significant 
reduction in the grade-3 and grade-4 mucositis in the honey, treated 
group of patients. 
Discussion 
This study has shown encouraging results for the prevention of 
symptomatic radiation mucositis. Though there was no significant 
change in the grade-1 & 2 mucositis, but the grade-3/4 mucositis was 
significantly reduced In the treatment arm. At present there is no study 
on honey available to compare, however comparing to a prospective 
~ 
!l 
.·J 
'1 
i 
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randomised trial In the use of povidone iodine oral rinse, the results are 
similar23 • But in our study ·we found an interesting observation 
regarding the change In body weight. In the study arm 55°/o of patients 
showed either static or gain In body weight during radiotherapy 
compared to 25°/o of patients on the control arm 
Radiation Induced mucositis is a normal accompaniment of radical 
radiotherapy to the head and neck area.· Normally the oral mucosa has 
a relatively high cell turnover rate. Exposure to ionising radiation leads 
to mucosal erythema, small whitish patches, and uiUmately results in 
confluent mucositis. In the later phases, oral ulceration and bleeding 
become a dose limiting toxicity. The mulcosltls Is a result of balance 
between cell loss and cell proliferation. The intensity of mucositis can 
be altered by new fractionation schedules, concurrent 
chemoradiotherapy, and co-morbid medical conditions. Bacterial 
colonization in the oral mucosa can exaggerate the mucositis. 
Endotoxins released from the gram-negative bacilli are potent mediator 
of the inflammatory process In the oral mucosa. Oropharyngeal flora 
too contribute to the radiation-Induced mucositis24-25 
Much has been reported about the mucositis and sornatitts, but a lack 
of consistency and use of grading criteria and reporting standards 
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makes it very difficult to draw comparative conclusions concerning 
toxicity end points among various trials. The lack of standardization 
remains problematic, In spite of recent efforts to· improve grading and 
reporting2 • 
In 1981, the World Health Organization published grading criteria for 
r 28 acute toxicities including mucositis26 • Subsequently I National Cancer 
Institute's (NCI) common toxicity criteria In 1983, which Included 49 
chemotherapy related toxicity criteria scales along with mucositls2 • On 
the next year an acute radiation toxicity system was published by 
Radiotherapy Treatment Oncology Group ( RTOG)21 , followed by 
different toxicity criteria frorn the Eastern Cooperative Oncology Group 
(ECOG) and the South-West Oncology Group (SWOG). The latter two 
groups were basically used for chemotherapy-induced toxicities. Hence 
RTOG Is one of the common toxicity scoring system to quantify 
radiation-Induced mucositis. 
The basis of management of radiation mucositis Is targeted to Its 4-
deflned pathogenesis. The most important of all Is to check growth of 
basal cell layer by modifying transforming growth factor-p3 27 • The 
second mechanism is by the rapid recovery of epttheHal cell loss by the 
stimulation of epithelization 2a-29 • Thirdly, by the chemical protection of 
13 
mucosa using aminothiol group of compounds like amtfostlne30 • The 
last but not the least, physical method of preventing radiation exposure 
to the oral mucosa by the use of shield, conformation therapy or 
Intensity modulated radiotherapy31 • Local antibiotics in the form of 
lozenges have been tried with a hope to prevent bacterial colonization 
and reduce Inflammation on the damaged mucosa. Low energy He/Ni 
laser treatment may promote the proliferation of mucosal cells and 
wound healing has been tried for the treatment of 
chemotherapy/radiotherapy-induced mucosltls32 • The above treatments 
are cumbersome and did not produce consistent resultso 
Honey Is a pure natural extract of pollens from the wild flowers 
gathered by the honeybee. There Is 4-types honey available for study 
I.e. sunflower, acacia, floral and wild floral type33 • It contains moisture, 
fructose, glucose, sucrose, maltose and other compounds along with 
trace elements34 • The quality of honey Is basically depends upon the 
type of source and dilution. Pure honey is ubiquitous, cheap and 
natural, exhibit antibacterial, analgesic, and tissue nutritive factors to 
stimulate re-epithellzation In the damaged mucosa, thereby a justified 
agent to try In radiation mucositis. Coating a wound with honey retard 
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tissue oxygenation by sealing the damaged mucosa off from air 
(oxygen). This could dampen pain within 30 seconds arter application. 
In the recent past, honey has been used for the treatment of burn 
wound, surgical infected wound, childhood diarrhoea, eye infections 
etc15, 35 • The philosophy of using honey In radiation mucositis was 
derived from the basic research and clinical observation of rapid 
epithelization in tissue injurles36-37 • In an experimental study by 
Bergman and co-workers, unbolled topical honey was applied to the 
open wound and the histopathological response was documented 
sequentially. The wound of the honey treated anirnals healed much 
faster than the wound of control animals (p value 0.001). According to 
this study, unbolled honey seems to accelerate wound healing when 
applied topically due to Its energy producing properties, Its hygroscopic 
effect on the wound, and Its bacteriostatic propertleso The important 
factors which Influences the effectiveness of honey are 
1. The hygroscopic nature of honey 
2 .Acidic pH of honey prevent bacteria to grow when applied to the 
mucosa 
3.Inhlblne (aka hydrogen peroxide) converted from glucose oxydase 
and gluconic acid 
4.Enzymes (growth factors?) and tissue nutritive minerals and vitamins 
of honey help repair tissue directly. 
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Bacterial growth In the oral cavity can aggravate the effect of radiation 
mucositis. Study conducted by AI-Tikriti et al demonstrated that 
oropharyngeal flora contribute to radiation induced mucosltis24 • 
Endotoxins released by gram-negative bacilli are potent mediators of 
an Inflammatory process25 • Use of topical antibiotics _like benzydamlne 
has shown slight Improvement In the control of mucositis. Another 
study by Rhan et al used povidone-Iodine oral rinse to reduce chemo-
radlotherapy Induced mucositis. In their small randomlsed-trlal, the 
severity and duration mucositis was reduced compared to controls 
treated with placebo (70°/o versus 100°/o) 23 • The antibacterial property 
of honey depends upon Its concentration38 • In our study we found 
bacterial growth inhibition around the honey drop, but the inhibition of 
the bacterial growth is inversely related to Its dilution (figure-la-d). 
Hence the reduction of radiation mucositis in honey treated patients 
might be due to bacteriostatic effect' of viscid honey. The same 
osmolarity based bacteriostasis was demonstrated In other studies39-40 • 
Pure honey is acidic with a pH of around 3.9 and the solubility-reducing 
factor present in honey can activate In absence of saliva. Honey applied 
on radiation induced xerotic mucosa Increases the rraicrohardness of 
enamel, there by prevent caries. Hence it has been postulated that 
honey Is less cariogenic in dry mouth patients 41 • In a recently 
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published report from Russian Academy of Medical Science, patients 
treated with honey laminolact in uterine cancer patients on 
radiotherapy showed significant decrease in the severity of radiation 
induced intestinal rnorbidity42 • 
In conclusion, from our small-randomised study, we found usefulness 
of pure natural honey in the management of symptomatic radiation 
mucositis. As this agent is effective in radiation mucositis, the same 
treatment could be useful in the management of chemotherapy induced 
oral stomatitis/mucositis and in the mucositis of bone marrow 
transplant patients. The philosophy of management in above conditions 
is similar. The further issue of use of medicinal honey need quality 
assurance of the natural honey, which might be different in different 
geographic locations, and source of pollens. As the future mu1Umodality 
approach of cancer lies in chemo-radlotherapy and altered fractionation 
schemes, prevention of oral rnucosltis is very important in their 
management. Honey could be a simple and cheap agent for the 
management of above morbidity. However, further randomised studies 
are essential to validate our findings. 
l 
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EORTC QLQ-C30 (vor:omn LO.) 
'Ne ;Jra interP.smd =n o;orng thinqs .mout '/(')U and ·rour heaith. P1erlse .1ns·NFH =111 .,{ tiHi •1uos1inns 
'!fJUr~e 1 r bv o:irr:::ing ~he r1umbor !hat best apolies to 'IOU. -:-here Jra no .. rignt'' tJr ···.·vrong'' 
answers. The inrormntton thst vou provtde w•ll remain strictly coniidenunl. 
PleasrJ fill in ·tour inititals: 
• 
I I 
Your birthdatG (Day, Month. Year): I I 
Todav's date (Day, Month. Yean= 31 
No Ya!J 
1. Do you havl! any trouble doing strenuous actrvittes. 
Uke carr(ing iJ heav'/ shopoing bag or a suitcase? 2 
,.. Do you hav'! any trouble taking a long walk? 2 
3. Co .10u ~~a''~ :Jnv trr,ubfe taking =1 shan w:Jik outsrde of tha hous~' 
., 
&.. 
c1 oo .10u h3'JI! to $tav in a bed or a -:hair for most of the day? 2 
5. Oo you need help with eating, dressing, washing yourself or 
using tho lorlet l, 2 
During the past week; Noq iU A Quli~ Vsr•t 
All llnl~ fll Bit Much 
6. Were you limited in doing either your work or other 
daily activities 1 2 3 d 
,·. 
'•Nor-, 'r'f'lt.J limited in purstJing 'fOUr hobbies or other 
leisure ~irne ac~i·1it!es 7 "' 3 •l 
"' 
3. \Nere .1ou ~hcrt 'Jf bre(tth? 2 3 4 
9. Hav~ ·tt)U hnd pain 1 "' 3 d ' 
10. Did ·1ou need to rest? 2 3 4 
11. Have you had trouble sleeping? 2 3 4 
1 2. Have you felt weal< 7 2 3 4 
13. Have you lacked appedts? 2 3 4 
1 J.. Have vou felt nauseated? 2 3 4 
1 s. Have ·1ou ''omit eo; 
.., 3 4 '-
~I 1 ~:\SH '10 •)n ~o the next Jage 
l'r Ml:U H.utU:II f 
,. ~, . . ' ,.. •\ 
During the pnst 'NP.P.!<: Not at A I)UittJ 'Jqrl 
All UtUo :t Bit Much 
16. Have you bean constmated? 
., 1 J 4 
1 -:-. Hav/3 •tou had ~~iarrhP..J? 2 .) z.l. 
13. \Nere '/OU ured? 2 3 4. 
,~ Oid pain interfere with your doily activities? 
., 3 4 
,.Jo 
£. 
20. Have you had difficult'/ in concentrating on things, 
like reading a new~ paper or watching television? 2 3 4 
21. Did you feal tense? 2 3 4. 
22. Did you worr'{1 2 3 4 
23. Did you feel irritable? 
., 3 d L 
24. Did you feel depr.;ssed? 
..., 3 4 
"' 
25. Have you had aiificult·1 remembering things? 2 3 J 
26. H.1 s •tour phvsical condition or medical treatment 
interfered with your famii•J life? 2 3 4 
., 
27. Has your physical condition or medical treatment 
interfered whh your social activities 7 . 1 2 3 4 
28. Has your physical co.ndition or medical treatment 
caused you financial difficulties? 1 2 3 4 
For the follo,Ning questions please circle the number between 1 and 7 that 
best appiies to you 
29 . How wo•Jid •tou rate your overall health during the past week? 
2 3 4 5 6 7 
Very poor 
3o. How would you rene your overall gualitv of life during the past W®9k7 
2 3 4 5 6 
verv poor. 
~ ·:Jn•,rr<l"'' '1'15 C:·JRTr: ·;ludv ]touo •>n •)u;uuv ,, 1.1fa .. \II r•oht! l't!U!Ivno. 
"" o;mn ~. ·J 
7 
Excellent 
I 
I 
P:Hients sometimes renort that they have the foilowtng :1ymotoms. Please lndJc::~te tina Axtont to 
·.vhlcn 'JOU have experienced t'lese ;,ymntoms durinq the past weok.; 
During ~t1c past ·n~ek : Not ~t A Quit~ 'ler.' 
All UtUe a Bit Mucn 
31. How much did you cough 7 1 2 J .l 
32. Cid you cough blood? 2 3 4 
33. 'Nere you short ot breath when 'IOU rested? 
., 3 J 4 
34. 'Nere you short"' breath when 'fOU •,•,aiked7 2 J J 
35. 'Nere you short of breath when you c!imbed stairs 7 2 3 J 
36. Have you had a sore rr.outh or !cr.gue? 
.... 3 .t ~ 
37. Have •tcu :1ad trrucie s·.vallowmg? "' 3 .1 ..
38. Have you had tingling ~ands or !es~? 
., 3 4 
" 
39. Have you had hair foss 1 2 3 4 
40. Have you had pal~ in your chest? 1 2 3 4 
41. Have you had pain in your arm or shoulder? 1 2 3 4 
42. Have you had pain in other parts of your .body? 1 2 3 4 
rr yes. •JVhere .................................................. -. 
dJ. Did 'jOIJ take ':Jn'/ mecicine for pain? 
~ No 2 Yes 
If '/f!S. hC'N much did il help 7 2 3 4 
·e ~~L'.J·G~O·!_C~J C.)oynqht 1994 E~RTC Slucty Group 'ln Quality of1ire /\ll · h 
· rtg ts reserved 
I 
~:Jr-\ 
~ 
,.... rn:u 1 t:nus-:n r 
EORTC QLQ-C30 tvor!:mn ::.o.1 
··~· ; ,:, . ·• 
·.ve .1ra interP.s~~d :n o;om~ mtnqs ·lnout '/C)U 1nn rcur 'leanh. ~•eose 1ns·.,..,,u Jtl .J( tlHlJ •Hms:inns 
.,,ur:;eaf b'l drc:ing ~he l"lumbor :nat best ape lies to 'IOU. 7hera Jra no .. riqnt ·• CJr ·• ..vronq ' 
answers. The !nmrmouon that you prov•ae wtll rernilln swctiv r.~niioenuai. 
Please fill :n ·rour inititais: 
Your birthdatB (Day, Month, Year): I ' I 
Todav's date (Day, Month, Yean: 31 I I 
No Yes 
1. Do you havl! anv rrouble do1ng strenuous acttvittes. 
Uke carrting a heavv shoooing bag or a suitcase? 2 
... Do you hav«! any trouble taking a long walk 1 2 
., 
... 3. Co .10u ~1a•11! 3n'l tr~ubfe taking =1 shan w<uk OlHStde of :he hol!s.~' 
11 Oo .10u ~a·1e to ~tav in a bed or a -:hair for most of the day? 2 
... 00 uou need help with eating, dressing, w3shing yourself or :l. 1 
using thG toilet 1, 2 
During the pas~ week; No~ tlU A Ouli® Vert 
AIU Unle a Bl~ Much 
6. Ware you limited in doing either y~ur work or other 
daily activitie91 2 3 
... '•Nore •;nu lirr.it~!d :n pursuing '/OUr hobbins Of other ; . 
leisure ·ime Jc~i·,it!eS? 2 3 ·1 
3. 'Ner!l •tt)U ~hort ')f '>reath? 2 3 .t 
9. Havf9 ·tOU hud pain 7 2 3 d 
10. Did '/OU need to rest? 2 3 4 
11. Have you had troubls sleeping? 2 3 4 
12. Havfl you (~?Jii weak7 2 3 4 
1J. Have you lacked appetite? 2 J 4 
1 d. Hnva '/OU h!!l~ nauseated? 2 J 4 
1 s. Have ·.tou •1omnea ( .., J ..t .;... 
~I 
t P.r\SR 10 ·1n ·o the next ~age 
t• r M ti> H.utn:n r 
0 . •h p s• 'VP.Qir• lHtng l e n ......... Not at .A I)UitiJ 'Jqrf 
AU LhUo :1 alt t\,1uch 
1 G. Have yiJU been .:onsuoated? 
, 
.1 J .;. 
t :-. HClvf3 vou had '~iarrntn? 
., 
.) :.l ._ 
13. 'N era •tau ~tr ed? 2 3 4 
1). Cid pain interfere with your datiX activities? 
., 3 4 
"" 
20. Have you had difficulty in concentrating on things. 
lika reading a newspaper or watching television? 2 3 4 
21. Did you feel tense? 2 3 4. 
22. Did '/OU worr'/1 2 3 .... 
23. Did you reel irritable? 
., 3 J. L 
Did you feel depressed? 
, 3 -.1 24. 4 
-,c::: 
~-· 
Have you had aiHic:..it·J remembering things? 2 J .l 
26. ..,:.1 s •rour physical condition or medical treatment 
intedered with your famil•t life? T 2 J 4 
·I 
27. Has your physical condition or medical treatment 
interfered with your social activities? .. 1 2 3 4 
28. Has your physical co.ndition or medical treatment 
caused you nnancia! difficulties? 1 2 3 4 
For the fcllo,Ning questions please circle the number between 1 and 7 that 
best appiies to you 
29 . How worJld •tou rate 'fOUr overall health during the past week? 
2 3 4 5 6 7 
Very poor 
0 HoW would you rate your overall quality of life dur;ng the paSlt ws~ak7 3 . 
2 3 4 5 6 7 
... 
verv poor. Excellent 
a : .. H1•1rtOf'l' '1f!5 ~·JRTt: :!udv JtrJUO •)M ·)u;uuv ,f '.•fe. -\II rtOIHS ;ltSIUVflO. 
Jtuo;ron 2. J · 
I 
I 
4/~ 
~ 
r= ·~ F.--:-C QL C1 
P'ltlents sometimes reoort that they have ·~he foilowlng :lymotoms. P1asss lndlc::~te 'h® axtont to 
whlcn 10u hav~ P.xpericnccd !'lese :;vmotoms cturinq the past wauk. 
ourtr.g tt1e past w~ek : Not at A Quit~ 'ler! 
All L!l\la a Blt Mucn 
How much did you cough? 1 
.... J J. 31. .l. 
32. Cid you cough blood? 
2 3 4 
'tVere you short ot breath when '/CU rested? ... 3 J 33. 4 
34. 'Nere you short of breath when ·;cu waiked? 
2 3 J 
35. 'Nere you short of breath when you c!imbed stairs? 2 3 
J 
36. Have •fCU had a sore rr.cuth or !cr.gue 7 
.... 3 J .... 
37. Ha'le 'fCU :1ad trr;ubie 3-.vallcwmg? 
"' 3 .1 ..
Have you had lingting ~ands or !eet? ., 3 4 38. .:. 
39. Have you had hair loss 1 2 3 4 
40. Have you had pal!' in your chest? 1 2 3 4 
41. Have you had pain in your arm or shoulder? 1 2 3 4 
42. Have you had pain in other parts of your _body? 1 2 3 4 
rr yes. •nhere .................................................. , 
£1:3. Oid 'fOIJ ~ake on'/ mecicine fer p::~in? 
~ No 2 Yes 
If 'Jf'!S. hew much ~ic il help 7 2 J 4 
·e ~~LG .c:o-tc 1 ::l C.JoywJht 1994 E~nrc Slutt•t Group 'ln Quality of ure "II · h 
· '' rrg ts resetved 
.IRAllJ)llATION MlUCOSll1rllS RESJEAIRCIHl 
SeriaD Nuunbell" 
Name 
Age 
BC Niimbew 
~IUSM Num~eJr 
Date of firs~ visui 
Diagnosis 
Gender MaUe/IF emaDe 
ECOG pe~rfou·mauu~e status 
IIistopathoBogy tr~port with number and date 
Aspirataon cytoUogy report and 11nnnber and date 
T~rea ~meuu\1 A.rJ.:uD A B.J 
DUADS 
1R&ce Ml&llmy/Ctt~u~tlllf:Se/lndRaniOfber 
QOL Sc~n·e 
1RT(Onco0@gy} N01m~er 
Date of D~s1 wusaa. 
TNM stage 1f N M 
Prior unetDksU nUUwes§ Diabetes UDype~rdension LeucopBakua orodentmB Jlroblem 
others 
!Plan of trea~meuuft IRadicaD Preoperative Irosto(lerative Ir~UUhuftuve Benign 
disease 
Prior anticance~· ~lluerapy Sa~~a-gery Radiotherapy ChemotDuera1~y hnmunotherapy 
Descriptoouu o~ t&-ue h11mor 
C~lldcmR Nasoendoscoji»y/ILaryngoscopy etc 
Radiotbera!l!y «lle~mB.Ils 
Field desag~n IPa~r®B~en oppose~ i-FieBd 2-Field 3-IFnUe:qll MuDti-fueUqJI 
Fieid Size • 2 UIIU CIJ1l1l 
Extent BOS-CILA V BOS ... MlllDNIEK MANDIBlLE-CfLA V MAND-MIDNEK 
Radua~hnt «iiose (fill11 Gy) lPhase-n Phase-[! l?Uuuse-UUI 
Fractioiiatuollll scllilerroue Gy F~ractions Weeks 
Dura!Uon of rJ!ldu®~llu~~rapy from ao 
Treatment iudervaOs Yes No 
Mucosiiis Gralllle-ll Grade-in Ga·ade-[11 GnuBe-llV Gg·ade-V 
Week-1 
Week-2 
Week-3 
Week-4 
Week-5 
Week-6 
Week-7 
Week-8 
[J11st put a cross SQgiD (X) at tire VIDeeti1og poi11t behvee1a week a1ui grlOde o/lllllcosidisJ 
Other compllUcatnons 
Tumor response Aa end of radiotherapy 4-week posi-lR"lf 8-week posa RT 
SKJN 
MUCOUS 
MEMBRANE 
EYE 
EAR 
SALIVARY 
GLAND 
RTOG Acute Radiation Mowbudity Scoring Crufte~rus 
(OJ ( 1 J [2] [ 4 I 
No !Follicular, faint or dull 
change jerythema/ epilation/dry 
over !desquamation/ decreased 
. Tender or bright 
:erythema, patchy moist 
!desquamation/ modemte 
;edema 
(3J 
iiConfluent, moist 
desqunmntiom other Utan 
lskin folds, pitting edema 
I 
i Ulceration, 
l hemorrhage, 
~necrosis 
baseline ;sweating 
No 
change 
over 
ba.c;eline 
No 
change 
No 
change 
over 
baseline 
No 
change 
over 
baseline 
! 
! 
jhtjectionl moy experience 
imild pain not requiring 
!anrugesic 
! 
i 
:Patch)' mucositis which 
lmay produce an 
iinflmnmntory 
:serosanguinitis 
/dischmge/ rnny 
;experience moderate 
pain requiring analgesia 
I 
!confluent fibrinous 
!mucositis/ rna)' include 
!severe pain requiriug 
I • 
l"arcobc 
' 
· !utcerntion, 
;hemorrhage or 
:necrosis 
' l 
I \Moderate conjunctivitis '!severe kerntiti'l with oomeal •I 
i d . . . . 'th i\\oith or Y.ithout kemtitis ulcerati'ool o'-.iecti've 'Lo~ ofvt'm'on 
'!Mil conJunctivitiS Wt or ' 'L'" "'~ 
· n1 :requiring sterojds &lor 11decrease m· "'l·sualacut'ty or ;,·(unilaternl or !Without scleml inJectio · 'b' · s1 d • 
. :anti totlc ry eye I' . 1 fi Ids/ i 'bilateral) jincreased tearmg ;requiring artificial tears/ m \1SUa Je acu e . . . 
',·: '.. . . 'th h 1 h b' :!glaucoma/ p!Ulopthnlmtlls l,' , mils WJ p o op o 1a . 
·~Miid ~temai ~iitis nilh . . .. ~M~~~t~ ~~~mal o~ti~ ·~~~~~·~~~~·~~;~ ~·u,·· . 
. erythema, pruritis, secondary ;requiring topical {disclumge or moist ; 
'Ito dry desquamation not 1 I 
jmcdicntionl serious otitis desquamation/ S)mptomatic : Deafncs.<1 requiring medication. h · 'h 'sf· · d · 
IAudiogmm unchanged from imediusl ypoacus1s on 1 ypoacust tinmtus, not rug ~ 
!bacreline 
iMHd mouth dryness/ slightly . 
!thickened sativa/ may have 
jsligbtly altered taste such os 
lmetallic ta.c;te/ these changes 
!not reflected in alteration in 
!baseline feeding behavior, 
!such a.q increased use of 
!liquids with meals 
i 
I h . 
:.·.testing only 
1
·related . :, 
i 
I 
!Moderate to complete 
,dryness/ thick, sticky 
;saliva/ mmkedly altered 
!taste 
' ; . 
l 
l 
.I 
; Acute salivary 
! gland necrosis 
I 
I 
i 
No 
PilAR YNX & change 
ESOPHAGUS over 
baseline 
rMifd dysp agta or 
!ooynnphagiol may require 
jtopicallUlesthetic or non· 
jnarcotio analgesics/ may 
(require soft diet 
:Moderate dysphagia or 
!od)nophngia/ mny 
require narcotic 
;Rnalgesicsl may require 
ipuree or liquid diet 
!severe dy~hugia or 
(odynophagia with 
!ctehydration or weight 
jloss(> 15% from pre-
jtreatment baseline) requiring 
!N-O feeding tube, I.V. fluids 
jor hnlettllimentation 
I 
:Complete 
! obrnuction, 
i ulceration, 
jperfomtion, 
.fistula n i 'i:i j :Persistent holll'Setless but j n\ 
I iable to vocnli7.el referred iwru~ h lh t :Mnrkecl dyspnea, n 
No !Mild or intennittent :ear pain, ~c throat. !pain ~;;;fi,= ~ pn~a . !stridor or ,U 
change !hoarseness/cough not 'Patchy fibnnous exudate i . . . 1hcmoptysis with )1 
over irequiring antitussive/ ;or mild arytenoid cdcnm lreq~mng narcottc/ confluent :tracheostomy or n 
I. ' lh f •n t · · t' 1 ;fibnnousexudate,morked !. 1 b 1. . : bnse me !ery ema o mucosa , o requmng narco tc ' t 'd ed !Jn u n ton r: 
i cough rcquidng 'ary enot etna inece.'lsary m 
! :antitussive ! • ,,1 
LARYNX 
.. 
' . ' • 0.~! ot>..h. I ,., r: ;..J....f.. • ." . • ~\!f_ ' ' •· !J. •• • • 
! KEIZINAN DILAKUKAN TATACARA 
~ DAN RAWATAN RADIOTERAPI 
. 
Saya .................................................................................. : ................. No. Kad Pengenalan .................................................... .. 
(na~) 
beralruna.t ..................................................................... dengan ini. mengizinkan tatacam da1l rawatan Radioterapi dilakulaul 
' I kea:tas ..................................... , ............................. , .......•.... : ................. , ............. No. KIP! ............... 4 •••••• , •••••••••••• , •••••••••• llllwk. 
(Saya/nama pesakilj 
pe1.1yal<it ............... · .......................................... yangruina siJat dan wjuann.ya te1ah diterangkan oleh Dr ......................................... .. 
mengikut1erjemahan ................................................. Beliaudeagan sepenuh kemampuan daa kebolebannyatelabll1Cllt.erjemab 
(penterjemah) 
·• 
kepada saya sifadankesan ra.watan tersebutdiatasdenganterang danjelas dalam bahasallogbat ................................................... .. 
tarikh ..................... : .................... pertalian ~ pesakit ............................................ •Tandatangan 
atau Cop Ibujari .............................. . 
(pe1aldtlwaris) 
DIBADAPAN 
NatJJa: ........................................... .. 
No.KIP ~ ......................................... .. T/Iangan .......................... . 
Jawutan: ........................................ .. (Saksi) 
Saya. sahkan babawa saya telah ~enerangkan kepada pesakitlwaris, sifat dan kescin tatacara dan ra.watan tersebut diatas. 
,
'L-!t.L. •••• ••••••••'•••••••••••••••••••• i;llll\J.l.········· . . 
/(eitit7dn me~tiloh ditandatangani olelr :-
1\utdatangaa: ........................ , ............... ' ........ : 
(Doktor Yang Merawalj 
CopRasmi 
(a) Jbubapa penjaga }ilea pesakit i dibawah umur 
a tau (b) Waris pesaiit yang berumur tidal lurang claril8 tahun jika pesakit itu tidal ten:laya dari segi mental ataufizikal. 
- ..,. ..... _ ..... -·lr·ln fu: law;GliiWUII')l6U_,. No.Pend. 
Nama 
. 
JABATAN PERUBATAN NUKLEAR, RADIOTERAPI, & ONKOLOGI 
Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan. 
PATIENT DATA & RADIATION PRESCRIPTION 
NAME: 
ADDRESS: 
DIAGNOSIS: 
INTENT : RADICAL I ADJIPALLIATIVE I MISC. 
DATE SITE & TECHNIQUE DOSE PRESCRIPTION 
R/N: OP/WARD: 
SEX/AGE: TEL. NO: 
CONSULTANT: 
PROTOCOL : AT I Chem-RT I RT-Chem 
RADIATION 
TYPE& 
ENERGY 
REPLAN 
& BOOST REMARKS 
--l-------+---------;-----1·-----f-------------
----1-------t---------~------JI------t------------
Diagram : Original field, black; Modification, green; Reduction, red. 
PRESCRIBED BY: DATE: 
.., 
" 
' j .,. 
'.... ... / 
TREATMENT SET-UP 
NUMBER 
FIELDS NAME 
JAWS 
SIZE 
SSD I SAD (PIN) 
GANTRY ANGLE 
COLLIMATOR ROTATION 
COUCH ROTATION 
W'GE ANG. & DIRECTION 
SHIELDING I CUT OUT 
APPLICATOR 
BOLUS OR WAX 
: 
' 
. 
PLANNING CALCULATION 
FIELDS Number 
Size 
Eqv. Square @ SAD 
. ~ 
Treatment Machine 
Radiation I Energy 
Separation AP I Lat 
.. 
SAD/ SSD I Ext. SSD 
SSD I SAD Factor 
Sc@ depth 
Sp@ depth 
POD I TMR @ depth 
Tray Factor 
Wedge Factor 
~~ig~ting 
Tumor Dose (cGy) 
----·-· 
MU 
Calc. By 
~---
Checked By 
.· 
I DAILY DOSE CHART 
,,. 
FIELD NO 
I SIZE TIME/M.U 
TUMOUR MONITOR MONITOR MONITOR MONITOR MONITOR TREAT CHECK 
I DOSE UNITS UNITS UNITS UNITS UNITS REMARKS NO. DATE TO DATE BY BY 
1 
I 2 3 
4 
I 5 6 
I 
7 
8 
9 
I 10 11 
12 
I 13 
14 
I 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 -
29 
-
30 
31 
32 
33 
34 
35 
---- .. 
36 
37 - ·------· 
38 
-
